Queues formed outside a sports hall at the University of Kent in March, months before most of the country had reason to think about meningitis at all. A nightclub in Canterbury had become the source of an outbreak that would kill two young people within days and leave dozens more seriously ill. Two months later, a similar cluster emerged around schools in Oxfordshire and Reading, claiming another life. By midsummer, NHS England had stopped treating these as isolated incidents and opened its largest ever meningitis B catch-up campaign, offering doses to roughly a million people who had missed the routine infant programme introduced in 2015. Within a fortnight, close to ninety thousand first doses had been given and more than 135,000 booking slots filled, the great majority of them not through GP surgeries or hospital clinics but across the counters of high street pharmacies.

That detail deserves more scrutiny than it has received. The campaign has been presented, reasonably enough, as a straightforward public health response to a run of deaths that unsettled parents and vaccination sceptics alike. It is also something else: a live test of a wager the government has already placed, that community pharmacy can absorb an ever larger share of NHS delivery without the funding or workforce to comfortably match it.

The sector has spent the past two years being asked to do more against a settlement its own representative body still calls inadequate. Pharmacy First expanded and then had independent prescribing added to it. Contraception services, hypertension case-finding and now a double-dose adolescent vaccine requiring a return visit within a strict twenty-eight day window all sit on top of core dispensing, itself strained by drug tariff changes and recurring medicine shortages. Community Pharmacy England has pointed to a structural funding gap it puts above two billion pounds, and pharmacies report being economically worse off than a year ago despite the 2025 uplift. Close to fifteen hundred pharmacies have closed since 2016, and tens of thousands of weekly opening hours have vanished from the network since 2022. The settlement agreed for 2026/27 brought a further increase, but the sector accepted it while making plain that acceptance was not the same as adequacy.

Set against that backdrop, a meningitis campaign built almost entirely around pharmacy delivery looks less like an obvious choice than the path of least resistance. General practice, already stretched by its own vaccination and appointment demands, was never going to move at the pace ministers needed after three deaths and rising parental anxiety. School-based programmes take months to organise properly. Pharmacies, with their extended hours and walk-in culture, were the only part of the system realistically able to hit a fortnight-old deadline. That they have delivered on volume so far is a genuine credit to the people running them. It also means that if second-dose uptake falls short, and coverage for follow-up doses typically does drop off, the political cost will land on a part of the system the government has not properly resourced to carry it.

This is the pattern now running through much of the wider NHS ten-year plan, inherited and continued by the current health secretary. Pharmacy is named as central to the shift toward prevention and neighbourhood care, with an expanded role in vaccination, screening and long-term condition management promised well before the money to underpin it was settled. Shifting activity into community settings only works if those settings are stable enough to bear the load. A network that has lost fifteen per cent of its outlets and a fifth of its real-terms funding since 2016 is not an obvious foundation for a national vaccination infrastructure, however capably individual pharmacists perform under pressure.

If the campaign succeeds, it will likely be remembered as proof that pharmacy-led prevention works. What it should prompt instead is a harder question about what the sector is being asked to hold up, and whether ministers are willing to fund the foundation rather than simply admire what has been built on top of it.